Gerry Davies

In this discussion, experts Chuck Peloquin, a TB treatment guideline contributor from the University of Florida, and Gerry Davies, an infection pharmacology professor at the University of Liverpool, delve into the complexities of rifampin dosing. They debate whether higher doses improve outcomes and explore toxicity thresholds. The duo also discusses alternative rifamycins and management strategies for patients with complications. Tune in for insights on optimizing treatment through therapeutic drug monitoring, especially for those with concurrent infections.